Abstract Library

#3049 Organoid Models of Neuroendocrine Cell Growth and Tumorigenesis

Introduction: A paucity of in vitro and in vivo models has limited the study of Neuroendocrine neoplasms (NENs). Moreover, little is known about normal neuroendocrine (NE) cells and how they contribute to NEN formation.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Dayton T, Den Hartigh L, Levy S, van den Berg J, Kok N,

Keywords: Organoids, NENs, pulmonary neuroendocrine cells,

#3021 Homecare Service for Administration of Lanreotide Autogel Injections: Assessment of Patients’ Experience

Introduction: In the past, all Neuroendocrine Neoplasm (NEN) patients (pts) on long-acting somatostatin analogues (SA), had to attend local hospitals/clinics to have them administered by nurses/doctors. Recently, a “homecare service” was developed, allowing pts to have their injections delivered to their home and injections were either administered by themselves, their partner or a Specialist Nurse (SN).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Gertner J

Authors: Gertner J, McSweeney A, Furtado O'Mahony L, Quaglia E, John A,

Keywords: homecare,

#2977 Predicting Survival in Patients with a Neuroendocrine Tumor of the Small Intestine (SI-NET)

Introduction: SI-NET comprise the largest group of neuroendocrine tumors. Because of their heterogeneity, predicting survival has proven challenging. A nomogram (NG) to assess SI-NET disease specific survival (DSS) has been developed in 2010 by Modlin, et al. based on analysis of retrospective data from the Surveillance, Epidemiology and End Results (SEER) database.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Levy S, van Veenendaal L, Korse C, Verbeek W, Vriens M,

Keywords: SI-NET, Nomogram, Survival,

#2961 Our Experience Using a New Scoring System to Detect Disease Recurrence after Curative Surgical Resection of Well-Differentiated Pancreatic Neuroendocrine Tumors

Introduction: For patients with nonfunctioning pNET  ≥20 mm in size without distant metastasis, complete surgical resection is recommended as the primary curative strategy. Effective follow‐up programs are designed to detect recurrence at an early stage, given that treatment of limited disease has the most favorable outcome. However, data on post‐curative surgical recurrence remains limited, making it challenging to determine the best follow‐up strategy and to detect the best treatment options as an adjuvant therapy for selected patients.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Mastrangelo L

Authors: Mastrangelo L, Cipressi C, Masetti M, Zanello M, Romboli A,

Keywords: nomogram, pancreatic neuroendocrine tumor, recurrence,

#2956 Somatostatin Analogs: The Economic Value of Lanreotide Autogel Delivery Attributes in the Treatment of GEP-NET versus Octreotide LAR – A UK Budget Impact Analysis

Introduction: Lanreotide autogel (LAN) and octreotide long acting release (OCT) are long-acting somatostatin analogues (LA-SSAs) used to treat patients (pts) with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). However, the treatments differ in terms of injection route, need for administration by a health care professional and dosing interval.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Feuilly M

Authors: Feuilly M, Cristeau O, Clay E, François C, Whalen J,

Keywords: somatostatin analogues, economics,